Authors: F. Benyettou, Y. Lalatonne, O. Sainte-Catherine, M. Lecouvey, L. Motte
Affilation: Laboratoire CSPBAT FRE 3043 CNRS, France
Pages: 40 - 43
Keywords: drug nanoparticle, Magnetic nanoparticle, Bisphosphonate, Cancer drugs, Drug targeting
We designed a new therapeutic nanoplatform which could be both imaged in situ with MRI (T2 contrast agent) and/or addressed by magnetic targeting (magnet) or specific molecules (peptides, antibodies …). The biological in-vitro tests performed on breast cancer cell line, MDA-MB 231, showed that free alendronate and Fe2O3@Alendronate have similar antiproliferative activity. In addition, we showed that the particles penetrate in cells by endocytosis uptake. Preliminary results of tests in vivo on nude mice show that Fe2O3@Alendronate has antiproliferative properties on breast cancer tumours. Indeed, under a magnetic field, we observed a significant slowdown of the tumours growth for Fe2O3@Alendronate treated mices whereas the free Alendronate molecules have no effect on the tumour growth.
Nanotech Conference Proceedings are now published in the TechConnect Briefs